J Fischer1, B Eberlein2, C Hilger3, F Eyer4, S Eyerich5, M Ollert3, T Biedermann1,2. 1. Department of Dermatology, Faculty of Medicine, Eberhard Karls University Tuebingen, Tuebingen, Germany. 2. Department of Dermatology and Allergy Biederstein, Technische Universität München, Munich, Germany. 3. Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg. 4. Department of Clinical Toxicology, Technische Universität München, Munich, Germany. 5. Center of Allergy and Environment, HMGU/Technische Universität München, Munich, Germany.
Abstract
BACKGROUND: Antivenoms are mammalian immunoglobulins with the ability to neutralize snake venom components and to mitigate the progression of toxic effects. Immediate hypersensitivity to antivenoms often occurs during the first administration of these heterologous antibodies. A comparable clinical situation occurred after introduction of cetuximab, a chimeric mouse-human antibody, for cancer treatment. The carbohydrate epitope galactose-alpha-1,3-galactose, located on the Fab region of cetuximab, was identified as the target responsible for IgE reactivity. OBJECTIVE: To investigate whether serum IgE antibodies directed to the α-gal epitope are associated with hypersensitivity to equine antivenoms. METHODS: Antivenoms were screened for α-gal epitopes via immunoblot and in comparison with cetuximab and pork kidney by IgE reactivity assays. Basophil activation tests were used to investigate reactivity to antivenoms in samples from 20 patients with specific IgE antibodies to α-gal and 10 controls. Additional IgE detection, IgE inhibition, ImmunoCAP inhibition, and skin prick tests were performed using samples from selected patients. RESULTS: Both antivenoms and cetuximab induced positive skin prick test results in patients with sIgE to α-gal. Alpha-gal epitopes were detected by immunoblotting on antivenoms. Measurements of IgE reactivity and ImmunoCAP inhibition indicated that the antivenoms contained lower α-gal contents than cetuximab. Deglycosylation assays and IgE inhibition tests confirmed that IgE-mediated reactivity to antivenom is associated with α-gal. Antivenoms, pork kidney, and cetuximab activated basophils from patients with IgE to α-gal. CONCLUSION: Alpha-gal is a potential target of IgE-mediated reactivity to equine antivenom and a possible cause of the high incidence of hypersensitivity reactions during the first application of equine antivenom.
BACKGROUND: Antivenoms are mammalian immunoglobulins with the ability to neutralize snake venom components and to mitigate the progression of toxic effects. Immediate hypersensitivity to antivenoms often occurs during the first administration of these heterologous antibodies. A comparable clinical situation occurred after introduction of cetuximab, a chimeric mouse-human antibody, for cancer treatment. The carbohydrate epitope galactose-alpha-1,3-galactose, located on the Fab region of cetuximab, was identified as the target responsible for IgE reactivity. OBJECTIVE: To investigate whether serum IgE antibodies directed to the α-gal epitope are associated with hypersensitivity to equine antivenoms. METHODS: Antivenoms were screened for α-gal epitopes via immunoblot and in comparison with cetuximab and pork kidney by IgE reactivity assays. Basophil activation tests were used to investigate reactivity to antivenoms in samples from 20 patients with specific IgE antibodies to α-gal and 10 controls. Additional IgE detection, IgE inhibition, ImmunoCAP inhibition, and skin prick tests were performed using samples from selected patients. RESULTS: Both antivenoms and cetuximab induced positive skin prick test results in patients with sIgE to α-gal. Alpha-gal epitopes were detected by immunoblotting on antivenoms. Measurements of IgE reactivity and ImmunoCAP inhibition indicated that the antivenoms contained lower α-gal contents than cetuximab. Deglycosylation assays and IgE inhibition tests confirmed that IgE-mediated reactivity to antivenom is associated with α-gal. Antivenoms, pork kidney, and cetuximab activated basophils from patients with IgE to α-gal. CONCLUSION:Alpha-gal is a potential target of IgE-mediated reactivity to equine antivenom and a possible cause of the high incidence of hypersensitivity reactions during the first application of equine antivenom.
Authors: Michael Levin; Danijela Apostolovic; Tilo Biedermann; Scott P Commins; Onyinye I Iweala; Thomas A E Platts-Mills; Eleonora Savi; Marianne van Hage; Jeffrey M Wilson Journal: Ann Allergy Asthma Immunol Date: 2019-03-26 Impact factor: 6.347
Authors: Thomas A E Platts-Mills; Scott P Commins; Tilo Biedermann; Marianne van Hage; Michael Levin; Lisa A Beck; Maria Diuk-Wasser; Uta Jappe; Danijela Apostolovic; Michael Minnicozzi; Marshall Plaut; Jeffrey M Wilson Journal: J Allergy Clin Immunol Date: 2020-02-10 Impact factor: 10.793
Authors: Matthew Straesser; Behnam Keshavarz; Larry Borish; Dilawar Khokhar; Angela Holian; Nathan P Charlton; Thomas A E Platts-Mills; Jeffrey M Wilson Journal: J Allergy Clin Immunol Pract Date: 2020-10-27
Authors: Thomas Luke; Richard S Bennett; Dawn M Gerhardt; Tracey Burdette; Elena Postnikova; Steven Mazur; Anna N Honko; Nicholas Oberlander; Russell Byrum; Dan Ragland; Marisa St Claire; Krisztina B Janosko; Gale Smith; Gregory Glenn; Jay Hooper; John Dye; Subhamoy Pal; Kimberly A Bishop-Lilly; Theron Hamilton; Kenneth Frey; Laura Bollinger; Jiro Wada; Hua Wu; Jin-An Jiao; Gene G Olinger; Bronwyn Gunn; Galit Alter; Surender Khurana; Lisa E Hensley; Eddie Sullivan; Peter B Jahrling Journal: J Infect Dis Date: 2018-11-22 Impact factor: 5.226